David Henry

Dr. David Henry

orcid

Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2016 in BMJ
Verified
Journal Article
Open access
PDF file
JSJonathan Ac Sterne
Jonathan Ac Sterne
MHMiguel A Hernán
Miguel A Hernán
BRBarnaby C Reeves
Barnaby C Reeves
JSJelena Savović
Jelena Savović
NBNancy D Berkman
Nancy D Berkman
JHJulian Pt Higgins
Julian Pt Higgins
Non-randomised studies of the effects of interventions are critical to many areas of healthcare evaluation, but their results may be biased. It is therefore important to understand and appraise their strengths and weaknesses. We developed ROBINS-I (“Risk Of Bias In Non-randomised Studies - of Interventions”), a new tool for evaluating risk of bias in estimates of the comparative effectiveness (harm or benefit) of interventions from studies that did not use randomisation to allocate units (individuals or clusters of individuals) to comparison groups. The tool will be particularly useful to those undertaking systematic reviews that include non-randomised studies.

21 September 2017 in BMJ
Verified
Journal Article
Open access
PDF file
BSBeverley J Shea
Beverley J Shea
BRBarnaby C Reeves
Barnaby C Reeves
GWGeorge Wells
George Wells
MTMicere Thuku
Micere Thuku
CHCandyce Hamel
Candyce Hamel
DHDavid Henry
David Henry
The number of published systematic reviews of studies of healthcare interventions has increased rapidly and these are used extensively for clinical and policy decisions. Systematic reviews are subject to a range of biases and increasingly include non-randomised studies of interventions. It is important that users can distinguish high quality reviews. Many instruments have been designed to evaluate different aspects of reviews, but there are few comprehensive critical appraisal instruments. AMSTAR was developed to evaluate systematic reviews of randomised trials. In this paper, we report on the updating of AMSTAR and its adaptation to enable more detailed assessment of systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. With moves to base more decisions on real world observational evidence we believe that AMSTAR 2 will assist decision makers in the identification of high quality systematic reviews, including those based on non-randomised studies of healthcare interventions.

17 June 2004 in BMJ
Verified
Journal Article
Closed access
PDF file
DADavid Atkins
David Atkins
DBDana Best
Dana Best
PBPeter A Briss
Peter A Briss
MEMartin Eccles
Martin Eccles
YFYngve Falck-Ytter
Yngve Falck-Ytter
GGGRADE Working Group
GRADE Working Group
Users of clinical practice guidelines and other recommendations need to know how much confidence they can place in the recommendations. Systematic and explicit methods of making judgments can reduce errors and improve communication. We have developed a system for grading the quality of evidence and the strength of recommendations that can be applied across a wide range of interventions and contexts. In this article we present a summary of our approach from the perspective of a guideline user. Judgments about the strength of a recommendation require consideration of the balance between benefits and harms, the quality of the evidence, translation of the evidence into specific circumstances, and the certainty of the baseline risk. It is also important to consider costs (resource utilisation) before making a recommendation. Inconsistencies among systems for grading the quality of evidence and the strength of recommendations reduce their potential to facilitate critical appraisal and improve communication of these judgments. Our system for guiding these complex judgments balances the need for simplicity with the need for full and transparent consideration of all important issues. Clinical guidelines are only as good as the evidence and judgments they are based on. The GRADE approach aims to make it easier for users to assess the judgments behind recommendations

1 October 2009 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
BSBeverley J. Shea
Beverley J. Shea
CHCandyce Hamel
Candyce Hamel
GWGeorge A. Wells
George A. Wells
LBLex M. Bouter
Lex M. Bouter
EKElizabeth Kristjansson
Elizabeth Kristjansson
MBMaarten Boers
Maarten Boers

22 December 2004 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
DADavid Atkins
David Atkins
MEMartin Eccles
Martin Eccles
SFSigne Flottorp
Signe Flottorp
Gordon H GuyattGordon H Guyatt
Gordon H Guyatt
DHDavid Henry
David Henry
TGThe GRADE Working Group
The GRADE Working Group
Background: A number of approaches have been used to grade levels of evidence and the strength of recommendations. The use of many different approaches detracts from one of the main reasons for having explicit approaches: to concisely characterise and communicate this information so that it can easily be understood and thereby help people make well-informed decisions. Our objective was to critically appraise six prominent systems for grading levels of evidence and the strength of recommendations as a basis for agreeing on characteristics of a common, sensible approach to grading levels of evidence and the strength of recommendations. Methods: Six prominent systems for grading levels of evidence and strength of recommendations were selected and someone familiar with each system prepared a description of each of these. Twelve assessors independently evaluated each system based on twelve criteria to assess the sensibility of the different approaches. Systems used by 51 organisations were compared with these six approaches. Results: There was poor agreement about the sensibility of the six systems. Only one of the systems was suitable for all four types of questions we considered (effectiveness, harm, diagnosis and prognosis). None of the systems was considered usable for all of the target groups we considered (professionals, patients and policy makers). The raters found low reproducibility of judgements made using all six systems. Systems used by 51 organisations that sponsor clinical practice guidelines included a number of minor variations of the six systems that we critically appraised. Conclusions: All of the currently used approaches to grading levels of evidence and the strength of recommendations have important shortcomings.

4 October 2006 in JAMA
Verified
Journal Article
Closed access
PDF file
PMPatricia McGettigan
Patricia McGettigan
DHDavid Henry
David Henry
Review from JAMA — Cardiovascular Risk and Inhibition of Cyclooxygenase — A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2 — ContextEvidence that rofecoxib increases the risk of myocardial infarction has led to scrutiny of other nonsteroidal anti-inflammatory drugs (NSAIDs). Regulatory agencies have provided variable advice regarding the cardiovascular risks with older nonselective NSAIDs.ObjectiveTo undertake a systematic review and meta-analysis of controlled observational studies to compare the risks of serious cardiovascular events with individual NSAIDs and cyclooxygenase 2 inhibitors.Data SourcesSearches were conducted of electronic databases (1985-2006), scientific meeting proceedings, epidemiological research Web sites, and bibliographies of eligible studies.Study SelectionEligible studies were of case-control or cohort design, reported on cardiovascular events (predominantly myocardial infarction) with cyclooxygenase 2 inhibitor, NSAID use, or both with nonuse/remote use of the drugs as the reference exposure. Of 7086 potentially eligible titles, 17 case-control and 6 cohort studies were included. Thirteen studies reported on cyclooxygenase 2 inhibitors, 23 on NSAIDs, and 13 on both groups of drugs.Data ExtractionTwo people independently extracted data and assessed study quality with disagreements resolved by consensus.Data SynthesisData were combined using a random-effects model. A dose-related risk was evident with rofecoxib, summary relative risk with 25 mg/d or less, 1.33 (95% confidence interval [CI], 1.00-1.79) and 2.19 (95% CI, 1.64-2.91) with more than 25 mg/d. The risk was elevated during the first month of treatment. Celecoxib was not associated with an elevated risk of vascular occlusion, summary relative risk 1.06 (95% CI, 0.91-1.23). Among older nonselective drugs, diclofenac had the highest risk with a summary relative risk of 1.40 (95% CI, 1.16-1.70). The other drugs had summary relative risks close to 1: naproxen, 0.97 (95% CI, 0.87-1.07); piroxicam, 1.06 (95% CI, 0.70-1.59); and ibuprofen, 1.07 (95% CI, 0.97-1.18).ConclusionsThis review confirms the findings from randomized trials regarding the risk of cardiovascular events with rofecoxib and suggests that celecoxib in commonly used doses may not increase the risk, contradicts claims of a protective effect of naproxen, and raises serious questions about the safety of diclofenac, an older drug.Published online September 12, 2006 (doi:10.1001/jama.296.13.jrv60011).